Trial · NCT05090566
Adverse event totals21
The totals the trial posted for each group.
1 to 20 of 21
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1 | 1 | 2 |
| Total, all-cause mortality | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2 | 3 | 6 |
| Total, all-cause mortality | SSA, Phase 1b: Elranatamab + Nirogacestat,Dose Level 3 | 3 | 10 |
| Total, all-cause mortality | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3A | 2 | 10 |
| Total, all-cause mortality | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A | 1 | 6 |
| Total, all-cause mortality | SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1 | 5 | 12 |
| Total, all-cause mortality | All Participants | 15 | 46 |
| Total, other adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1 | 2 | 2 |
| Total, other adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2 | 6 | 6 |
| Total, other adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat,Dose Level 3 | 10 | 10 |
| Total, other adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3A | 10 | 10 |
| Total, other adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A | 6 | 6 |
| Total, other adverse events | SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1 | 11 | 12 |
| Total, other adverse events | All Participants | 45 | 46 |
| Total, serious adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1 | 1 | 2 |
| Total, serious adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2 | 5 | 6 |
| Total, serious adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat,Dose Level 3 | 6 | 10 |
| Total, serious adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3A | 6 | 10 |
| Total, serious adverse events | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A | 4 | 6 |
| Total, serious adverse events | SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1 | 7 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05090566/event-totals